Gag-CA Q110D mutation elicits TRIM5-independent enhancement of HIV-1mt replication in macaque cells

Microbes and Infection

Volumn 15, Issue 1, 2013, Pages 56-65

  Nomaguchi, Masako ^a   Yokoyama, Masaru ^b   Kono, Ken ^c   Nakayama, Emi E ^c   Shioda, Tatsuo ^c   Saito, Akatsuki ^d   Akari, Hirofumi ^d   Yasutomi, Yasuhiro ^e   Matano, Tetsuro ^b   Sato, Hironori ^b   Adachi, Akio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Gag CA; HIV 1; HIV 1mt; Macaque cells; Molecular modeling; Virus growth

Indexed keywords

GAG PROTEIN; TRIPARTITE MOTIF PROTEIN 5;

ANIMAL CELL; ARTICLE; CLONE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANIMALS; CAPSID PROTEINS; CARRIER PROTEINS; CATS; CELL LINE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MACACA; MUTAGENESIS, SITE-DIRECTED; MUTATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE; PRIMATES;

EID: 84871786654     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.10.013     Document Type: Article

References (50)

1. Malim M.H., Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398.
2. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010, 8:55-67.
3. Shibata R., Sakai H., Kawamura M., Tokunaga K., Adachi A. Early replication block of human immunodeficiency virus type 1 in monkey cells. J. Gen. Virol. 1995, 76:2723-2730.
4. Nomaguchi M., Doi N., Kamada K., Adachi A. Species barrier of HIV-1 and its jumping by virus engineering. Rev. Med. Virol. 2008, 18:261-275.
5. Nomaguchi M., Adachi A. Virology as biosystematics: towards understanding the viral infection biology. Front. Microbiol. 2010, 1:2.
6. Holmes R.K., Malim M.H., Bishop K.N. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem. Sci. 2007, 32:118-128.
7. Huthoff H., Towers G.J. Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol. 2008, 16:612-619.
8. Strebel K., Luban J., Jeang K.T. Human cellular restriction factors that target HIV-1 replication. BMC Med. 2009, 7:48.
9. Luban J. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. 2007, 81:1054-1061.
10. Towers G.J. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007, 4:40.
11. Nakayama E.E., Shioda T. Anti-retroviral activity of TRIM5 alpha. Rev. Med. Virol. 2010, 20:77-92.
12. Newman R.M., Hall L., Connole M., Chen G.L., Sato S., Yuste E., Diehl W., Hunter E., Kaur A., Miller G.M., Johnson W.E. Balancing selection and the evolution of functional polymorphism in old world monkey TRIM5alpha. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19134-19139.
13. Wilson S.J., Webb B.L., Ylinen L.M., Verschoor E., Heeney J.L., Towers G.J. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3557-3562.
14. Price A.J., Marzetta F., Lammers M., Ylinen L.M., Schaller T., Wilson S.J., Towers G.J., James L.C. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat. Struct. Mol. Biol. 2009, 16:1036-1042.
15. Ylinen L.M., Price A.J., Rasaiyaah J., Hué S., Rose N.J., Marzetta F., James L.C., Towers G.J. Conformational adaptation of Asian macaque TRIMCyp directs lineage specific antiviral activity. PLoS Pathog. 2010, 6:e1001062.
16. Kamada K., Igarashi T., Martin M.A., Khamsri B., Hatcho K., Yamashita T., Fujita M., Uchiyama T., Adachi A. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16959-16964.
17. Igarashi T., Iyengar R., Byrum R.A., Buckler-White A., Dewar R.L., Buckler C.E., Lane H.C., Kamada K., Adachi A., Martin M.A. Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J. Virol. 2007, 81:11549-11552.
18. Kamada K., Yamashita T., Hatcho K., Adachi A., Nomaguchi M. Evasion from CypA- and APOBEC-mediated restrictions is insufficient for HIV-1 to efficiently grow in simian cells. Microbes Infect. 2009, 11:164-171.
19. Saito A., Nomaguchi M., Iijima S., Kuroishi A., Yoshida T., Lee Y.J., Hayakawa T., Kono K., Nakayama E.E., Shioda T., Yasutomi Y., Adachi A., Matano T., Akari H. Improved capacity of a monkey-tropic HIV-1 derivative to replicate in cynomolgus monkeys with minimal modifications. Microbes Infect. 2011, 13:58-64.
20. Kuroishi A., Saito A., Shingai Y., Shioda T., Nomaguchi M., Adachi A., Akari H., Nakayama E.E. Modification of a loop sequence between alpha-helices 6 and 7 of virus capsid (CA) protein in a human immunodeficiency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) vif and CA alpha-helices 4 and 5 loop improves replication in cynomolgus monkey cells. Retrovirology 2009, 6:70.
21. Yamashita T., Doi N., Adachi A., Nomaguchi M. Growth ability in simian cells of monkey cell-tropic HIV-1 is greatly affected by downstream region of the vif gene. J. Med. Invest. 2008, 55:236-240.
22. Yamashita M., Emerman M. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 2004, 78:5670-5678.
23. Lebkowski J.S., Clancy S., Calos M.P. Simian virus 40 replication in adenovirus-transformed human cells antagonizes gene expression. Nature 1985, 317:169-171.
24. Akari H., Fukumori T., Iida S., Adachi A. Induction of apoptosis in herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86. Biochem. Biophys. Res. Commun. 1999, 263:352-356.
25. Doi N., Fujiwara S., Adachi A., Nomaguchi M. Growth ability in various macaque cell lines of HIV-1 with simian cell-tropism. J. Med. Invest. 2010, 57:284-292.
26. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59:284-291.
27. O'Doherty U., Swiggard W.J., Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 2004, 74:10074-10080.
28. Howard B.R., Vajdos F.F., Li S., Sundquist W.I., Hill C.P. Structural insights into the catalytic mechanism of cyclophilin A. Nat. Struct. Biol. 2003, 10:475-481.
29. Deshpande N., Addess K.J., Bluhm W.F., Merino-Ott J.C., Townsend-Merino W., Zhang Q., Knezevich C., Xie L., Chen L., Feng Z., Green R.K., Flippen-Anderson J.L., Westbrook J., Berman H.M., Bourne P.E. The RCSB protein data bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res. 2005, 33(Database issue):D233-D237.
30. Song H., Nakayama E.E., Yokoyama M., Sato H., Levy J.A., Shioda T. A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. J. Virol. 2007, 81:7280-7285.
31. Kono K., Song H., Yokoyama M., Sato H., Shioda T., Nakayama E.E. Multiple sites in the N-terminal half of simian immunodeficiency virus capsid protein contribute to evasion from rhesus monkey TRIM5α-mediated restriction. Retrovirology 2010, 7:72.
32. Inagaki N., Takeuchi H., Yokoyama M., Sato H., Ryo A., Yamamoto H., Kawada M., Matano T. A structural constraint for functional interaction between N-terminal and C-terminal domains in simian immunodeficiency virus capsid proteins. Retrovirology 2010, 7:90.
33. Labute P. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem. 2008, 29:1693-1698.
34. Ponder J.W., Case D.A. Force fields for protein simulations. Adv. Protein Chem. 2003, 66:27-85.
35. Onufriev A., Bashford D., Case D.A. Modification of the generalized Born model suitable for macromolecules. J. Phys. Chem. B 2000, 104:3712-3720.
36. Lin T.Y., Emerman M. Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1. Virology 2008, 379:335-341.
37. Kuroishi A., Bozek K., Shioda T., Nakayama E.E. A single amino acid substitution of the human immunodeficiency virus type 1 capsid protein affects viral sensitivity to TRIM5 alpha. Retrovirology 2010, 7:58.
38. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004, 427:848-853.
39. Keckesova Z., Ylinen L.M., Towers G.J. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to old world monkey but not human TRIM5 alpha antiviral activity. J. Virol. 2006, 80:4683-4690.
40. Sokolskaja E., Berthoux L., Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J. Virol. 2006, 80:2855-2862.
41. Lim S.Y., Rogers T., Chan T., Whitney J.B., Kim J., Sodroski J., Letvin N.L. TRIM5alpha modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathog. 2010, 6:e1000738.
42. Onyango C.O., Leligdowicz A., Yokoyama M., Sato H., Song H., Nakayama E.E., Shioda T., de Silva T., Townend J., Jaye A., Whittle H., Rowland-Jones S., Cotten M. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. Vaccine 2010, 28:B60-B67.
43. Kinomoto M., Appiah-Opong R., Brandful J.A., Yokoyama M., Nii-Trebi N., Ugly-Kwame E., Sato H., Ofori-Adjei D., Kurata T., Barre-Sinoussi F., Sata T., Tokunaga K. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin. Infect. Dis. 2005, 41:243-251.
44. Gitti R.K., Lee B.M., Walker J., Summers M.F., Yoo S., Sundquist W.I. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 1996, 273:231-235.
45. Tang C., Ndassa Y., Summers M.F. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat. Struct. Biol. 2002, 9:537-543.
46. Yokoyama M., Naganawa S., Yoshimura K., Matsushita S., Sato H. Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop. PLoS One 2012, 7:e37530.
47. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
48. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252.
49. Sauter D., Schindler M., Specht A., Landford W.N., Münch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., Takehisa J., Ogando Y., Ochsenbauer C., Kappes J.C., Ayouba A., Peeters M., Learn G.H., Shaw G., Sharp P.M., Bieniasz P., Hahn B.H., Hatziioannou T., Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6:409-421.
50. Shingai M., Yoshida T., Martin M.A., Strebel K. Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo. J. Virol. 2011, 85:9708-9715.